Lanciprol

Lansoprazole, the active ingredient in Lanciprol, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to treat conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease, Helicobacter pylori infection and erosive esophagitis.

GNH USA supplies Lanciprol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export markets. Customers benefit from reliable lead times and comprehensive after‑sales support.

Lansoprazole is indicated for several gastrointestinal acid‑related conditions. - Gastro‑oesophageal reflux disease (GERD): reduces acid exposure, relieving heartburn and promoting healing of the esophageal lining. - Peptic ulcer disease: promotes ulcer healing by decreasing gastric acidity. - Helicobacter pylori eradication: used in combination therapy to increase eradication rates. - Erosive esophagitis: facilitates mucosal repair by maintaining a higher gastric pH.

Lansoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools, usually self‑limiting. - Nausea: occasional feeling of stomach upset. - Abdominal pain: cramping or discomfort in the stomach area.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea and abdominal pain. - Interstitial nephritis: kidney inflammation causing reduced urine output and flank pain. - Stevens‑Johnson syndrome: rare skin reaction with blistering and mucosal involvement. - Hepatic injury: elevated liver enzymes or jaundice.

Before prescribing Lansoprazole, clinicians should consider several safety and handling precautions. - Assess renal function: dose adjustment may be required in severe impairment. - Review concomitant medications: potential interactions can affect efficacy or safety. - Monitor for osteoporosis: long‑term use may reduce calcium absorption. - Use caution in pregnancy: limited data, prescribe only if benefit outweighs risk. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Lansoprazole can alter the plasma concentrations of several drugs, requiring attention to interaction risk.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular events. - Atazanavir (and other protease inhibitors): decreased absorption, loss of antiviral efficacy. - Ketoconazole and other azole antifungals: markedly reduced bioavailability.

Moderate Interactions (Monitor Closely): - Warfarin: enhanced anticoagulant effect, monitor INR. - Digoxin: increased serum levels, observe for toxicity. - Methotrexate (high dose): reduced renal clearance, watch for toxicity.